Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: Efficient hypothesis testing through hierarchical phylogenetic models

Molecular Biology and Evolution

Volumn 28, Issue 5, 2011, Pages 1605-1616

  Edo Matas, Diana ^a   Lemey, Philippe ^b   Tom, Jennifer A ^c   Serna Bolea, Cèlia ^a,e   Van Den Blink, Agnes E ^a   Van 'T Wout, Angélique B ^a,f   Schuitemaker, Hanneke ^a,f   Suchard, Marc A ^c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Bayesian inference; CCR5; disease progression; envelope; hierarchical phylogenetic models; HIV 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 DELTA32; GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MOLECULAR CLONING; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; NONHUMAN; NUCLEOTIDE SEQUENCE; STOCHASTIC MODEL; UNINDEXED SEQUENCE; VIRUS ISOLATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BAYES THEOREM; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; GENE DELETION; GENOTYPE; HETEROZYGOTE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MODELS, GENETIC; PHYLOGENY; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955417630     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msq326     Document Type: Article

References (69)

1. Blaak H, Ran LJ, Rientsma R, Schuitemaker H. 2000. Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. Virology 267:237-246. (Pubitemid 30123606)
2. Borrow P, Lewicki H, Wei X, et al (11 co-authors). 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 3:205-211. (Pubitemid 27064706)
3. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, Sodroski J. 1997. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol. 71:9808-9812. (Pubitemid 27492434)
4. Carvajal-Rodriguez A, Posada D, Perez-Losada M, Keller E, Abrams EJ, Viscidi RP, Crandall KA. 2008. Disease progression and evolution of the HIV-1 env gene in 24 infected infants. Infect Genet Evol. 8:110-120.
5. Casella G, George EI. 1992. Explaining the Gibbs sampler. Am Stat. 46:167-174.
6. Casella G, Robert C. 1996. Rao-Blackwellisation of sampling schemes. Biometrika 83:81-94.
7. Chackerian B, Rudensey LM, Overbaugh J. 1997. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol. 71:7719-7727. (Pubitemid 27391717)
8. Chipman H, George E, McCulloch R. 2001. The practical implementation of Bayesian model selection. IMS Lect Notes Monogr Ser. 38:67-134.
9. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267:483-489.
10. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. 1999. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol. 163:4597-4603. (Pubitemid 29474531)
11. de Roda Husman AM, Koot M, Cornelissen M, et al. (14 co-authors). 1997. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med. 127:882-890. (Pubitemid 27490625)
12. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H. 1999. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis. 180:1106-1115. (Pubitemid 30070193)
13. de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, Roos M, Coutinho R, Miedema F, Goudsmit J. 1997. AIDS prognosis based on HIV-1 RNA, CD4\+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 11:1799-1806. (Pubitemid 27500955)
14. Drummond AJ, Ho SYW, Phillips MJ, Rambaut A. 2006. Relaxed phylogenetics and dating with confidence. PLoS Biol. 4:e88.
15. Drummond AJ, Rambaut A. 2007. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol. 7:214.
16. Gelman A, Carlin JB, Stern HS, Rubin DB. 1995. Bayesian data analysis. New York: Chapman & Hall/CRC.
17. Geskus RB. 2000. On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion. Stat Med. 19:1753-1769. (Pubitemid 30436061)
18. Goldman N, Yang Z. 1994. A codon-based model of nucleotide substitution for protein-coding DNA sequences. Mol Biol Evol. 11:725-736.
19. Goulder PJ, Phillips RE, Colbert RA, et al. 12 co-authors. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 3:212-217. (Pubitemid 27064707)
20. Gray ES, Moore PL, Choge IA, et al. 13 co-authors. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol. 81:6187-6196. (Pubitemid 46878025)
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
22. Hoeting J, Madigan D, Raftery A, Volinsky C. 1999. Bayesian model averaging. Stat Sci. 14:382-401.
23. Hollingsworth TD, Laeyendecker O, Shirreff G, et al. (14 co-authors). 2010. HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog. 6:e1000876.
24. Hubert L, Arabie P. 1985. Comparing partitions. J Classification. 2:193.
25. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. (32 co-authors). 2001. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 135:782-795. (Pubitemid 33051262)
26. Jeffreys H. 1998. Theory of probability. New York: Oxford University Press.
27. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 77:13376-13388. (Pubitemid 37494331)
28. Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8\+ cytotoxic T lymphocyte response. J Exp Med. 200:1243-1256. (Pubitemid 39552566)
29. Kemal KS, Foley B, Burger H, et al. (17 co-authors). 2003. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci USA. 100:12972-12977. (Pubitemid 37340010)
30. Kitchen CM, Lu J, Suchard MA, Hoh R, Martin JN, Kuritzkes DR, Deeks SG. 2006. Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res Hum Retroviruses. 22:1260-1266. (Pubitemid 46095244)
31. Kitchen CM, Philpott S, Burger H, Weiser B, Anastos K, Suchard MA. 2004. Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral therapy: a Bayesian approach. J Virol. 78:11296-11302. (Pubitemid 39299669)
32. Kitchen CMR, Marconi V, Kuritzkes DR, Bloomquist EW, Deeks SG, Suchard MA. 2009. Two-way Bayesian hierarchical phylogenetic models: an application to the co-evolution of gp120 and gp41 during partial treatment interruptions of enfuvirtide. Comput Stat Data Anal. 53:766-775.
33. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiemstra H, Schuitemaker H. 2003. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis. 188:864-872. (Pubitemid 37176033)
34. Kootstra NA, Schuitemaker H. 1999. Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macro-phages. Virology 253:170-180. (Pubitemid 29393303)
35. Kuo L, Mallick B. 1998. Variable selection for regression models. Sankhya B. 60:65-81.
36. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. 2003. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis. 187:1397-1403. (Pubitemid 36549684)
37. Laird NM, Ware JH. 1982. Random-effects models for longitudinal data. Biometrics 38:963-974.
38. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. 1985. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 313:79-84. (Pubitemid 15068701)
39. Lee HY, Perelson AS, Park SC, Leitner T. 2008. Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol. 4:e1000240.
40. Lemey P, Kosakovsky Pond SL, Drummond AJ, Pybus OG, Shapiro B, Barroso H, Taveira N, Rambaut A. 2007. Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol. 3:e29.
41. Lemey P, Rambaut A, Drummond AJ, Suchard MA. 2009. Bayesian phylogeography finds its roots. PLoS Comput Biol. 5:e1000520.
42. Mellors JW, Rinaldo CR Jr., Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170. (Pubitemid 26001148)
43. Miedema F, Petit AJ, Terpstra FG, et al. (11 co-authors). 1988. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4\+ T helper cell depletion occurs. J Clin Invest. 82:1908-1914. (Pubitemid 19054937)
44. Munoz A, Sabin CA, Phillips AN. 1997. The incubation period of AIDS. AIDS. 11(Suppl A):S69-S76.
45. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol. 78:5205-5215. (Pubitemid 38581472)
46. Polk BF, Fox R, Brookmeyer R, Kanchanaraksa S, Kaslow R, Visscher B, Rinaldo C, Phair J. 1987. Predictors of the acquired immunodeficiency syndrome developing in a cohort of sero-positive homosexual men. N Engl J Med. 316:61-66. (Pubitemid 17052739)
47. Potter SJ, Lemey P, Dyer WB, Sullivan JS, Chew CB, Vandamme AM, Dwyer DE, Saksena NK. 2006. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology 348:35-46.
48. Repits J, Sterjovski J, Badia-Martinez D, et al. 13 co-authors. 2008. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 379:125-134.
49. Rodrigo AG, Goode M, Forsberg R, Ross HA, Drummond A. 2003. Inferring evolutionary rates using serially sampled sequences from several populations. Mol Biol Evol. 20:2010-2018. (Pubitemid 38057765)
50. Ross HA, Rodrigo AG. 2002. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol. 76:11715-11720. (Pubitemid 35231326)
51. Sagar M, Wu X, Lee S, Overbaugh J. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol. 80:9586-9598. (Pubitemid 44435633)
52. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from mono-cytotropic to T-cell-tropic virus population. J Virol. 66: 1354-1360.
53. Seo TK, Kishino H, Thorne JL. 2004. Estimating absolute rates of synonymous and nonsynonymous nucleotide substitution in order to characterize natural selection and date species divergences. Mol Biol Evol. 21:1201-1213. (Pubitemid 38823723)
54. Shankarappa R, Margolick JB, Gange SJ, et al. (12 co-authors). 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 73:10489-10502.
55. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. 2002. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol. 64:583-639.
56. Stamatatos L, Cheng-Mayer C. 1998. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol. 72:7840-7845. (Pubitemid 28421774)
57. Stamatatos L, Wiskerchen M, Cheng-Mayer C. 1998. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res Hum Retroviruses. 14:1129-1139. (Pubitemid 28409165)
58. Sterjovski J, Churchill MJ, Ellett A, et al. 16 co-authors. 2007. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4:89.
59. Suchard MA, Kitchen CM, Sinsheimer JS, Weiss RE. 2003. Hierarchical phylogenetic models for analyzing multipartite sequence data. Syst Biol. 52:649-664. (Pubitemid 37365046)
60. Suchard MA, Rambaut A. 2009. Many-core algorithms for statistical phylogenetics. Bioinformatics 25:1370-1376.
61. Suchard MA, Weiss RE, Sinsheimer JS. 2001. Bayesian selection of continuous-time Markov chain evolutionary models. Mol Biol Evol. 18:1001-1013. (Pubitemid 32520473)
62. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680. (Pubitemid 24354800)
63. van 't Wout AB, Schuitemaker H, Kootstra NA. 2008. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat Protoc. 3:363-370.
64. Veugelers PJ, Page KA, Tindall B, et al. (11 co-authors). 1994. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol. 140:747-758. (Pubitemid 24322187)
65. Vrancken B, Lequime S, Theys K, Lemey P. 2010. Covering all bases in HIV research: unveiling a hidden world of viral evolution. AIDS Rev. 12:89-102.
66. Wang WK, Dudek T, Essex M, Lee TH. 1999. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc Natl Acad Sci USA. 96:4558-4562. (Pubitemid 29190375)
67. Wei X, Decker JM, Wang S, et al. (15 co-authors). 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
68. Wei X, Ghosh SK, Taylor ME, et al. (12 co-authors). 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
69. Williamson S. 2003. Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol. 20:1318-1325. (Pubitemid 36961250)